机译:FDA批准摘要:NIRAPARIB用于维持经常性卵巢癌患者的患者,以应对铂基化疗
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD 20993 USA;
机译:FDA批准摘要:NIRAPARIB用于维持经常性卵巢癌患者的患者,以应对铂基化疗
机译:尼拉帕里布作为铂类化疗后经常性卵巢癌维修治疗的预算影响
机译:患有复发性卵巢癌患者的二线铂类化疗的治疗选择:积极监测和维持治疗比较
机译:提高转移性肿瘤分割的功效,以促进卵巢癌患者对化疗的反应的早期预测
机译:卵巢癌患者的DNA修复SNP与铂类化疗的预后之间的关联。
机译:FDA批准摘要:Nivolumab用于治疗转移性非小细胞肺癌铂类化学疗法或之后的进展
机译:尼拉帕里布患者患有复发性卵巢癌后的脑内反应患者在engot-OV16 / Nova试验中的最后一铂基化疗后